biotech / news / / Fox News
A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial.
The TroFuse-005 trial is the first global Phase 3 to show survival improvement over chemo for endometrial cancer.
KEY POINTS
- Sacituzumab tirumotecan is the first antibody-drug conjugate to achieve such results in this setting.
- The trial included 776 advanced endometrial cancer patients whose disease progressed after both platinum chemo and immunotherapy.
- Merck has not yet disclosed detailed statistics on survival benefit and response rates for sacituzumab tirumotecan.
COMPANIES
Summarized by Newsio from Fox News. How we summarize →